BDAZ - The only thing I would add to your comments about the 30% RRR, CV death reduction and 3 Point MACE reduction would be increased kidney function and better cognitive function for the trial participants affected that these secondary end points may provide. We can only hope that they talk ALL of this up a lot if our results are as good as what they are hoping for.

That talk needs to be both to the science community and the the investment community with emphasis on the investment community.

tada